1. Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country
by Lorena Lobo de Figueiredo-Pontes, Maria Isabel Ayrosa Madeira, Luisa Koury Corrêa de Araujo, Priscila Santos Scheucher, Fabíola Traina, Ana Silvia Gouvêa de Lima, Katia Pagnano, Ronald Pallota, Rosane Bittencourt, Maria de Lourdes Chauffaille, Marcos Roberto Pedron Oltramari, Marcia Higashi, Rodrigo Miguel Bendlin, Elaine Coustan-Smith, Dario Campana, and Eduardo Magalhães Rego
BloodAdv
Volume 1(Suppl):80-83
December 8, 2017
© 2017 by The American Society of Hematology

2. Study workflow.
Study workflow. Before immunophenotypic analysis, BM slides are reviewed to confirm diagnosis or posttreatment morphological remission. In cases where morphology cannot define the acute leukemia phenotype as myeloid or lymphoid, a screening study is performed by using an orientation antibody panel including CD45, CD34, myeloperoxidase, CD19, CD79a, CD3, CD7. LAIPs are defined in BM samples at diagnosis, after each course of therapy, pre–autologous stem cell transplantation, post–autologous stem cell transplantation, and every 3 months thereafter for 2 years. In addition, a sample of stem cell–enriched peripheral blood harvested for autologous transplant is analyzed.
Lorena Lobo de Figueiredo-Pontes et al. Blood Adv 2017;1:80-83
© 2017 by The American Society of Hematology

3. Representative MPFC analysis of AML at diagnosis (upper panels) and MRD1 (lower panels).
Representative MPFC analysis of AML at diagnosis (upper panels) and MRD1 (lower panels). After sample preparation, cells are labeled with the antibody mixture to identify the backbone leukemic blasts (CD45, CD34, CD117 and CD33, panel A) followed by combinations of fluorochrome-conjugated monoclonal antibodies directed to the leukemic phenotypes (CD38, HLA-DR, CD11b, CD7, CD4, CD56, CD13, CD19, CD11c, CD64, CD133, CD15, NG2, and CD41 (examples in B) at room temperature in the dark. Blast cells are identified by using the gating templates defined at diagnosis. The staining tubes that define the LAIPs at diagnosis are then repeated at the MRD points of study.
Lorena Lobo de Figueiredo-Pontes et al. Blood Adv 2017;1:80-83
© 2017 by The American Society of Hematology